| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 501 | 2021 |
| Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates P Maisonnasse, J Guedj, V Contreras, S Behillil, C Solas, R Marlin, ... Nature 585 (7826), 584-587, 2020 | 395 | 2020 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 368 | 2021 |
| Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia A Pizzorno, B Padey, T Julien, S Trouillet-Assant, A Traversier, ... Cell Reports Medicine 1 (4), 2020 | 251 | 2020 |
| Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load A Gonçalves, J Bertrand, R Ke, E Comets, X De Lamballerie, D Malvy, ... CPT: pharmacometrics & systems pharmacology 9 (9), 509-514, 2020 | 228 | 2020 |
| Influenza viruses and mRNA splicing: doing more with less J Dubois, O Terrier, M Rosa-Calatrava MBio 5 (3), 10.1128/mbio. 00070-14, 2014 | 173 | 2014 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 150 | 2022 |
| In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 A Pizzorno, B Padey, J Dubois, T Julien, A Traversier, V Dulière, P Brun, ... Antiviral research 181, 104878, 2020 | 146 | 2020 |
| Critical role of segment-specific packaging signals in genetic reassortment of influenza A viruses B Essere, M Yver, C Gavazzi, O Terrier, C Isel, E Fournier, F Giroux, ... Proceedings of the National Academy of Sciences 110 (40), E3840-E3848, 2013 | 131 | 2013 |
| Extracellular HSP27 mediates angiogenesis through Toll‐like receptor 3 D Thuringer, G Jego, G Wettstein, O Terrier, L Cronier, N Yousfi, ... The FASEB Journal 27 (10), 4169-4183, 2013 | 121 | 2013 |
| Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy A Pizzorno, B Padey, O Terrier, M Rosa-Calatrava Frontiers in immunology 10, 531, 2019 | 120 | 2019 |
| Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response V Marcel, K Fernandes, O Terrier, DP Lane, JC Bourdon Cell Death & Differentiation 21 (9), 1377-1387, 2014 | 109 | 2014 |
| Cold oxygen plasma technology efficiency against different airborne respiratory viruses O Terrier, B Essere, M Yver, M Barthélémy, M Bouscambert-Duchamp, ... Journal of Clinical Virology 45 (2), 119-124, 2009 | 103 | 2009 |
| COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study Infection 49 (5), 889-905, 2021 | 90 | 2021 |
| Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a O Terrier, J Textoris, C Carron, V Marcel, JC Bourdon, M Rosa-Calatrava Journal of General Virology 94 (5), 985-995, 2013 | 88 | 2013 |
| Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release S Eymieux, Y Rouillé, O Terrier, K Seron, E Blanchard, M Rosa-Calatrava, ... Cellular and Molecular Life Sciences 78, 3565-3576, 2021 | 79 | 2021 |
| Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia D Asarnow, B Wang, WH Lee, Y Hu, CW Huang, B Faust, PML Ng, ... Cell 184 (12), 3192-3204. e16, 2021 | 71 | 2021 |
| The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses F Durupt, D Koppers-Lalic, B Balme, L Budel, O Terrier, B Lina, L Thomas, ... Cancer gene therapy 19 (1), 58-68, 2012 | 71 | 2012 |
| Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives Q Le Hingrat, B Visseaux, C Laouenan, S Tubiana, L Bouadma, ... Clinical Microbiology and Infection 27 (5), 789. e1-789. e5, 2021 | 69 | 2021 |
| Viral and bacterial co-infection in severe pneumonia triggers innate immune responses and specifically enhances IP-10: a translational study J Hoffmann, D Machado, O Terrier, S Pouzol, M Messaoudi, W Basualdo, ... Scientific reports 6 (1), 38532, 2016 | 60 | 2016 |
Andrés PizzornoCentre International de Recherche en Infectiologie (CIRI) - Team VirPath, Lyon, FranceVerified email at univ-lyon1.fr
